Compare Cassava Sciences Inc (FLNA) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while iShares 3 7 Year Treasury Bond ETF trades at $116.82. Which is the better fit depends on your goals.
| FLNA | IEI | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $120.72 |
52-Week Low | $1.09 | $116.45 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
iShares 3-7 Year Treasury Bond ETF (IEI) trades at $116.865, showing minimal daily movement with a 0.11% gain. The technical outlook is bearish, with moving averages signaling downward pressure. The ETF has paid consistent dividends recently, including $0.37 in May 2026 and $0.36 in April 2026. Financial media comparisons highlight IEI's focus on intermediate-term U.S. Treasuries, offering lower volatility than corporate bond alternatives but facing yield competition from broader bond ETFs.
The outlook for IEI is tied to Federal Reserve policy and bond market dynamics. Rising rate hike expectations create headwinds for intermediate-term Treasury ETFs, while inflation concerns may shift investor preference toward inflation-protected securities. The ETF's government debt focus provides safety during market stress but limits yield potential compared to corporate bond funds, presenting a trade-off between stability and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
